Alnylam Pharmaceuticals, Inc. (ALNY) News
Filter ALNY News Items
ALNY News Results
|Loading, please wait...|
ALNY News Highlights
- 500 - Internal server error
- Over the past 27 days, the trend for ALNY's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about ALNY are RNA, DE and DRNA.
Latest ALNY News From Around the Web
Below are the latest news stories about Alnylam Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNY as an investment opportunity.
Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from a Phase 3b open-label study conducted to evaluate the safety, efficacy and pharmacokinetics (PK) of patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy progression after receiving an orthotopic liver transplant (OLT). In patients treated with patisiran, the median reduction in serum TTR levels compared to baseline was 91 percent, measured as an aver
Over the past few years, Cathie Wood's ARK Invest group of exchange-traded funds have delivered impressive gains. ARK Invest's most successful fund over the past year, the ARK Genomic Revolution ETF (NYSEMKT: ARKG) has the best performer of the bunch with an incredible 80% gain over the past 12 months. On Jun. 3, 2021, the ARK Genomic Revolution ETF bought shares of these two clinical-stage biotechs.
Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of cardiomyopathy in patients with transthyretin-mediated (ATTR) amyloidosis. Enrollment was completed with over 300 ATTR amyloidosis patients across 90 sites in more than 20 countries. ATTR amyloidosis is a rare, progressively debilitating, and fatal disease that is caused by misfolded transthyretin (TTR) proteins that accumulate as amyloid deposits in multiple tissues, including the nerves, heart and gastrointestinal (GI) tract and encompasses hereditary ATTR (hATTR) amyloidosis and wild-type ATTR (wtATTR) amyloidosis. hATTR amylo...
Photo by CROCOTHERY/iStock via Getty Images RNA interference (or RNAi) specialist Alnylam Pharmaceuticals (ALNY) has held up okay in what has been a tougher tape for biotech, with the shares down about 5% since my last update versus a 15% decline for the SPDR S&P Biotech ETF (XBI). Since that...
With the business potentially at an important milestone, we thought we'd take a closer look at Alnylam Pharmaceuticals...
Photo by libre de droit/iStock via Getty ImagesDicerna Pharmaceuticals (DRNA) specializes in RNAi (RNA interference) therapies. This has become a major field for pharmaceutical companies in the last few years and promises to be a value generator for this coming decade. I am updating my thesis because when I wrote...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has started a clinical study of a biannual dosing regimen of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis. The study is being conducted during a randomized treatment extension (RTE) period in the HELIOS-A Phase 3 study, and will characterize the safety, efficacy, and TTR reduction of a 50 mg biannual dosing regimen of subcutaneously administered vutrisiran in patients with hereditary ATTR (hATTR) amyloidosis with polyneuropathy. In addition, the Company announces today advancement of a new pre-clinical ATTR amyloidosis program aimed at achieving highly potent and reversible TTR reduction of over 90 p...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences which are being held virtually:
Evercore ISI Stick to Their Buy Rating for Alnylam Pharmaceuticals
Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive early results on clinical outcome measures from the 12-month analysis of ILLUMINATE-A Phase 3 study of OXLUMO® (lumasiran), an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – for the treatment of primary hyperoxaluria type 1 (PH1). These data were presented at the American Society of Pediatric Nephrology (ASPN)/Pediatric Academic Societies (PAS) virtual meeting being held on April 30–May 4, 2021.